Halozyme Therapeutics, Inc. (HALO) Posts Q1 Loss of 22c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St set for higher open as AI stocks rise, oil slides
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- Wall St set for higher open as AI stocks rise, oil slides
Halozyme Therapeutics (HALO) Q1 Report 'Solid' on Multiple Fronts - BMO Capital
May 13, 2014 6:26 AM EDTBMO Capital analyst Jim Birchenough, M.D. reiterated an Outperform rating and $24 price target on Halozyme Therapeutics (NASDAQ: HALO) following Q1 results which showed a strong HERCEPTIN SC launch, and progress on the PEGPH20 clinical hold as the company announced that the Data... More
